Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuncay Goksel

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Journal of Breath Research|February 8, 2020
Concordance in molecular genetic analysis of tumour tissue, plasma, and exhaled breath condensate samples from lung cancer patientsAslı Tetik Vardarli, Levent Pelit, Ceyda Aldag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2008
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2023
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung CancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapyMaurice Pérol, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Journal of Cardiovascular Pharmacology|February 23, 2013
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxelPierre Maison-Blanche, Jan B Vermorken, Tuncay Goksel, et al.
Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
BMC Cancer|November 22, 2018
Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 CountriesAnna Rich, David Baldwin, Inmaculada Alfageme, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Journal of Breath Research|February 8, 2020
Concordance in molecular genetic analysis of tumour tissue, plasma, and exhaled breath condensate samples from lung cancer patientsAslı Tetik Vardarli, Levent Pelit, Ceyda Aldag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2008
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2023
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung CancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapyMaurice Pérol, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Journal of Cardiovascular Pharmacology|February 23, 2013
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxelPierre Maison-Blanche, Jan B Vermorken, Tuncay Goksel, et al.
Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
BMC Cancer|November 22, 2018
Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 CountriesAnna Rich, David Baldwin, Inmaculada Alfageme, et al.
Pageof 5